Spero Therapeutics, Inc. SPRO NASDAQ

Spero Therapeutics, Inc. (SPRO) reported total assets of $68.92M and total liabilities of $9.9M for fiscal year 2025, resulting in total equity of $59.02M.

The company held $40.27M in cash and short-term investments. Total debt stood at $2.9M, with net debt of $-37.37M. The Debt-to-Equity (D/E) ratio was 0.05 (conservative).

Current ratio is 7.59, indicating strong short-term liquidity.

Criteria supported by this page:

• HEALTH (100/100, Pass) — Debt-to-Equity of 0.05, current ratio of 7.59 — balance sheet is strong
• MOAT (50/100) — Total assets $68.92M and equity $59.02M support the company's competitive scale
• VALUE (93/100) — Debt-to-Equity 0.05 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 61/100 with 2/7 criteria passed.

NUVB

Nuvation Bio Inc.

$4.82

-0.72%

CTMX

CytomX Therapeutics, Inc.

$4.56

+0.44%

ASMB

Assembly Biosciences, Inc.

$29.81

+1.26%

ACHL

Achilles Therapeutics plc

$1.48

+0.68%

TIL

Instil Bio, Inc.

$8.89

+5.33%

NXTC

NextCure, Inc.

$12.02

-5.87%

NLTX

Neoleukin Therapeutics, Inc.

$3.49

+1.45%

LLY

Eli Lilly and Company

$905.13

-1.88%